Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Thrombosis and Stroke

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

BMJ

Bradbury AW, Hall JA, Popplewell MA, Meecham L, Bate GR, Kelly L, Deeks JJ, Moakes CA, BASIL-3 Investigators

doi: 10.1136/bmj-2024-080881

Cardiovascular Risk and DiseasesTherapy and Intervention

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Lancet

Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY, SMART-CHOICE 3 investigators

doi: 10.1016/S0140-6736(25)00449-0

SPECIAL REPORT

Atrial Fibrillation

Considerations When Switching Direct Oral Anticoagulation Therapy in Patients with Non-Valvular Atrial Fibrillation

Heart, Artery and Coronary Diseases

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Lancet

Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Otsuki H, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B

doi: 10.1016/S0140-6736(25)00505-7

Atrial Fibrillation

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

JAMA Cardiol

Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, Steffel J, Russo AM, van Gelder IC, Ferdinand KC, Lopes RD, Mundl H, Benczur B, Gómez-Doblas JJ, Glikson M, Goudev A, Grove EL, Halvorsen S, Kiviniemi T, Martin AC, Sandhu RK, Vinereanu D, Rockhold FW, Caso V, Coppolecchia R, Patel MR

doi: 10.1001/jamacardio.2025.0277

Atrial FibrillationFurther Publications

Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial

Circ Cardiovasc Interv

Fanaroff AC, Wojdyla DM, Granger CB, Goodman SG, Aronson RS, Windecker S, Mehran R, Alexander JH, Lopes RD

doi: 10.1161/CIRCINTERVENTIONS.123.013596

Heart Failure

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Lancet Healthy Longev

Balata M, Radbruch L, Hesse M, Westenfeld R, Neukirchen M, Pfister R, Batzler YN, Öztürk C, Kavsur R, Tiyerili V, Weltermann B, Pölsler R, Standl T, Nickenig G, Becher MU, Heart Failure Network Rhineland

doi: 10.1016/j.lanhl.2024.08.006

Atrial FibrillationThrombosis and Stroke

Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial

J Am Heart Assoc

Diener HC, Becher N, Sehner S, Toennis T, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Beuger V, Calvert M, Camm AJ, Chlouverakis G, Dan GA, Dichtl W, Fierenz A, Goette A, de Groot JR, Hermans A, Lip GYH, Lubinski A, Marijon E, Merkely B, Mont L, Nikorowitsch J, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Simantirakis E, Vardas P, Wichterle D, Zapf A, Kirchhof P, NOAH‐AFNET 6 investigators

doi: 10.1161/JAHA.124.036429

Heart, Artery and Coronary DiseasesTherapy and Intervention

SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial

Lancet

Terkelsen CJ, Freeman P, Dahl JS, Thim T, Nørgaard BL, Mogensen NSB, Tang M, Eftekhari A, Povlsen JA, Poulsen SH, Pedersen L, Hjort J, Ellert J, Christiansen EH, Sørensen HT, Nissen H

doi: 10.1016/S0140-6736(25)00106-0

Related content

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Considerations When Switching Direct Oral Anticoagulation Therapy in Patients with Non-Valvular Atrial Fibrillation

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial

SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial